Seattle Genetics, Inc. and Takeda Pharmaceutical Company Limited today reported data demonstrating that Hodgkin lymphoma patients at risk of relapse following an autologous stem cell transplant who received ADCETRIS as consolidation therapy immediately after ASCT had significant improvement in progression-free survival compared to patients who received placebo . The data from the AETHERA trial were featured at the 56th American Society of Hematology Annual Meeting press program today and will be presented in an oral session on December 8, 2014.
http://ift.tt/1wc60IM
http://ift.tt/1wc60IM
No comments:
Post a Comment